Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 16 | 2023 | 87 | 2.070 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 13 | 2023 | 24 | 1.570 |
Why?
|
| Immunosuppressive Agents | 12 | 2023 | 135 | 0.930 |
Why?
|
| Natalizumab | 3 | 2019 | 15 | 0.710 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2019 | 98 | 0.680 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2020 | 119 | 0.670 |
Why?
|
| Filgrastim | 1 | 2019 | 5 | 0.670 |
Why?
|
| Immunologic Factors | 2 | 2019 | 39 | 0.670 |
Why?
|
| JC Virus | 1 | 2019 | 82 | 0.610 |
Why?
|
| Immunoglobulin G | 6 | 2020 | 129 | 0.520 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2009 | 92 | 0.320 |
Why?
|
| Disease Progression | 4 | 2020 | 812 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2019 | 1247 | 0.290 |
Why?
|
| Interferon Regulatory Factor-1 | 3 | 2011 | 5 | 0.280 |
Why?
|
| Adult | 22 | 2020 | 8741 | 0.270 |
Why?
|
| Aquaporin 4 | 2 | 2014 | 6 | 0.230 |
Why?
|
| Neuromyelitis Optica | 2 | 2014 | 5 | 0.230 |
Why?
|
| Central Nervous System Diseases | 1 | 2023 | 21 | 0.220 |
Why?
|
| Female | 24 | 2020 | 16412 | 0.210 |
Why?
|
| Humans | 31 | 2023 | 29814 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 4 | 2011 | 270 | 0.200 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 3 | 2011 | 43 | 0.200 |
Why?
|
| Male | 18 | 2020 | 15851 | 0.190 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2020 | 6 | 0.180 |
Why?
|
| Middle Aged | 19 | 2016 | 9960 | 0.170 |
Why?
|
| Gadolinium | 2 | 2016 | 11 | 0.160 |
Why?
|
| Treatment Outcome | 9 | 2023 | 3561 | 0.150 |
Why?
|
| Double-Blind Method | 6 | 2016 | 522 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2023 | 3325 | 0.140 |
Why?
|
| Brain | 3 | 2019 | 1726 | 0.140 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2016 | 8 | 0.140 |
Why?
|
| 4-Aminopyridine | 2 | 1991 | 4 | 0.120 |
Why?
|
| Transplantation Conditioning | 3 | 2006 | 35 | 0.120 |
Why?
|
| Muscular Diseases | 1 | 2014 | 18 | 0.120 |
Why?
|
| Spinal Cord Compression | 1 | 2014 | 31 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2023 | 1859 | 0.120 |
Why?
|
| Quality of Life | 2 | 2013 | 677 | 0.120 |
Why?
|
| Cladribine | 2 | 2023 | 2 | 0.110 |
Why?
|
| Tablets | 2 | 2023 | 8 | 0.110 |
Why?
|
| Central Nervous System | 3 | 2023 | 56 | 0.110 |
Why?
|
| Aquaporins | 1 | 2012 | 7 | 0.110 |
Why?
|
| Escherichia coli Proteins | 1 | 2012 | 9 | 0.110 |
Why?
|
| Decompression, Surgical | 1 | 2014 | 144 | 0.110 |
Why?
|
| Autoimmune Diseases | 2 | 2006 | 64 | 0.100 |
Why?
|
| Demyelinating Diseases | 1 | 2011 | 9 | 0.100 |
Why?
|
| Cyclophosphamide | 4 | 2023 | 56 | 0.100 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2011 | 1 | 0.100 |
Why?
|
| Oligodendroglia | 1 | 2011 | 26 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2011 | 9 | 0.090 |
Why?
|
| Neuroglia | 1 | 2011 | 39 | 0.090 |
Why?
|
| Young Adult | 5 | 2020 | 1966 | 0.090 |
Why?
|
| Cervical Vertebrae | 1 | 2014 | 352 | 0.090 |
Why?
|
| DNA | 1 | 2010 | 122 | 0.090 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 14 | 0.080 |
Why?
|
| Recurrence | 2 | 2023 | 354 | 0.080 |
Why?
|
| Disability Evaluation | 3 | 2009 | 327 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2010 | 127 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 60 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2011 | 492 | 0.080 |
Why?
|
| Animals | 6 | 2012 | 4634 | 0.070 |
Why?
|
| Mice | 4 | 2012 | 1629 | 0.070 |
Why?
|
| Injections, Subcutaneous | 2 | 2016 | 35 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 456 | 0.060 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2003 | 2 | 0.060 |
Why?
|
| Europe | 2 | 2014 | 85 | 0.060 |
Why?
|
| Adolescent | 3 | 2013 | 2332 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 200 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2011 | 202 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2012 | 682 | 0.040 |
Why?
|
| Rabbits | 2 | 2012 | 283 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2011 | 310 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 1641 | 0.040 |
Why?
|
| Astrocytoma | 1 | 1999 | 26 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 436 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1462 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 1999 | 102 | 0.040 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1999 | 34 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 191 | 0.040 |
Why?
|
| Spinal Cord | 1 | 1999 | 106 | 0.040 |
Why?
|
| Transplantation, Autologous | 3 | 2009 | 197 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2016 | 1952 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 1998 | 224 | 0.040 |
Why?
|
| Nasopharyngitis | 1 | 2016 | 2 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 6 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2016 | 12 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 22 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2016 | 19 | 0.030 |
Why?
|
| Safety | 1 | 2016 | 48 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 23 | 0.030 |
Why?
|
| Whole-Body Irradiation | 3 | 2003 | 18 | 0.030 |
Why?
|
| Muscle Fatigue | 1 | 1996 | 10 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 32 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 2016 | 68 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2016 | 57 | 0.030 |
Why?
|
| Pneumonia | 1 | 2016 | 67 | 0.030 |
Why?
|
| Fatigue | 1 | 1996 | 63 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2003 | 379 | 0.030 |
Why?
|
| Antilymphocyte Serum | 2 | 2009 | 3 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2014 | 33 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 1996 | 802 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 177 | 0.030 |
Why?
|
| Structural Homology, Protein | 1 | 2012 | 5 | 0.030 |
Why?
|
| Cross Reactions | 1 | 2012 | 25 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2012 | 13 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 230 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 232 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2012 | 69 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 191 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 241 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 254 | 0.030 |
Why?
|
| Aged | 2 | 2014 | 9620 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2010 | 364 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2011 | 16 | 0.020 |
Why?
|
| Placebos | 1 | 1991 | 82 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 156 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1996 | 1187 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 60 | 0.020 |
Why?
|
| Movement | 1 | 1991 | 146 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 256 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2010 | 12 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 411 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 683 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 103 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 58 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2010 | 45 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 57 | 0.020 |
Why?
|
| Plasma | 1 | 2010 | 34 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 81 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2010 | 62 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2010 | 78 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 75 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2009 | 4 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 10 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 2010 | 92 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 173 | 0.020 |
Why?
|
| Inflammation | 1 | 2011 | 347 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 81 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1998 | 12 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 223 | 0.020 |
Why?
|
| Antigens, CD34 | 2 | 1998 | 16 | 0.020 |
Why?
|
| Methylprednisolone | 2 | 1998 | 24 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 532 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 558 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 286 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2009 | 403 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 744 | 0.020 |
Why?
|
| Spinal Fusion | 1 | 2014 | 518 | 0.020 |
Why?
|
| Factor VIII | 1 | 2006 | 27 | 0.020 |
Why?
|
| Biomarkers | 1 | 2010 | 704 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 1126 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2003 | 161 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 1999 | 25 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 1998 | 5 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1998 | 23 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 1999 | 54 | 0.010 |
Why?
|
| Torque | 1 | 1996 | 29 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1998 | 204 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1996 | 84 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1998 | 507 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1996 | 641 | 0.010 |
Why?
|
| Vision Disorders | 1 | 1990 | 24 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1990 | 144 | 0.010 |
Why?
|
| Reaction Time | 1 | 1990 | 124 | 0.010 |
Why?
|